contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bibbinstruments-ab-bibbinstruments-announces-date-for-conversion-of-exercised-warrants-of-series-to-1-into-shares

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BiBBInstruments är verksamt inom medicinteknik. Bolaget utvecklar biopsiinstrument baserat på sin egenutvecklade teknologiplattform. Tekniken används huvudsakligen inom specialistsjukvården och kirurgavdelningar vid behandling av olika cancerformer. Produkterna säljs som engångsinstrument med framtagen borrfunktion och används vid stadiet av diagnostisering. Bolaget grundades 2013 och har sitt huvudkontor i Lund.

BiBBInstruments

BiBBInstruments AB ("BiBB" or the "Company") announces that the Swedish Companies Registration Office has registered the shares subscribed for through the exercise of warrants of series TO 1...

<div class="abstract">BiBBInstruments AB ("BiBB" or the "Company") announces that the Swedish Companies Registration Office has registered the shares subscribed for through the exercise of warrants of series TO 1 ("TO 1"). A total of 514,916 TO 1 were exercised for the subscription of 514,916 shares in the Company. This increases the number of shares in the Company to 40,739,302 and the share capital in the Company increases by SEK 43,767.86 to SEK 3,462,840.67. The record date is June 26, 2025, after which it is expected that the shares will be admitted to trading on Spotlight Stock Market and distributed to subscribers' VP accounts/custody accounts as of June 30, 2025.</div>AdvisorsDNB Carnegie SME and Setterwalls Advokatbyrå AB acted as financial and legal advisors to BiBB in connection with the rights issue through which TO 1 were issued.This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.For more information about BiBB, please contact: Fredrik Lindblad, CEO E-mail: fredrik.lindblad@bibbinstruments.com Phone: +46 70 899 94 86 www.bibbinstruments.com About BiBBBiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® - the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and EndoDrill® URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BIBB) is listed on Spotlight Stock Market.&nbsp;<h2>IMPORTANT INFORMATION</h2>The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.&nbsp;<div></div>

BibbInstruments AB: BiBBInstruments announces date for conversion of exercised warrants of series TO 1 into shares